Specifically, the HMGB2-positive rates in CD3-CD56+ and CD3-CD16+CD56+ NK cells in ESCC patients were 66.45 ± 2.03% (p < 0.001) and 67.02 ± 2.05% (p < 0.001), respectively—both significantly higher than in healthy controls. The gene discussed is HMGB2; the disease is esophageal squamous cell carcinoma.